PF513 MUTATIONS AFFECTING THE CREBBP HAT DOMAIN PREDICT RESPONSE TO MTOR INHIBITORS EVEROLIMUS AND TEMSIROLIMUS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Emil Kumar(Queen Mary University of London), Jude Fitzgibbon(Queen Mary University of London), Findlay Bewicke‐Copley(Queen Mary University of London), Anne J. Novak(Mayo Clinic), Maria Calaminici(Queen Mary University of London), Koorosh Korfi(Queen Mary University of London), Alejo Efeyan(Spanish National Cancer Research Centre), Kathrine S Rallis(Beth Israel Deaconess Medical Center), Thomas E. Witzig(WinnMed), Jessica Okosun(Queen Mary University of London), Stephen M. Ansell(Mayo Clinic), J. Wang(Institute of Cancer Research), Michael Leukam(Beth Israel Deaconess Medical Center), Andrew Clear(Queen Mary University of London), J S Scott(University of Chicago), Sonali M. Smith(University of Chicago)
Cited by 0
Related Papers
mTOR: from growth signal integration to cancer, diabetes and ageing
|Nature Reviews Molecular Cell Biology|2010|4k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
mTORC1 Senses Lysosomal Amino Acids Through an Inside-Out Mechanism That Requires the Vacuolar H <sup>+</sup> -ATPase
|Science|2011|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Senescence in premalignant tumours
|Nature|2005|1.5k